The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma
- PMID: 2648877
The immunohistochemical diagnosis of mesothelioma. Differentiation of mesothelioma and lung adenocarcinoma
Abstract
Despite numerous histochemical, ultrastructural, and immunohistochemical studies, differentiation between malignant epithelial pleural mesothelioma and adenocarcinoma of the lung remains extremely difficult. Although there is general agreement that immunohistochemical methods can aid in this distinction, some studies have produced conflicting results with some of the proposed markers for mesothelioma. To obtain comparable and reproducible results, 19 unequivocal epithelial mesotheliomas and 23 unequivocal primary lung adenocarcinomas were studied by the avidin-biotin-peroxidase complex method on formalin-fixed, paraffin-embedded tissue specimens. Well-characterized, commercially available antibodies to carcinoembryonic antigen (CEA), a high- and low-molecular-weight keratin, vimentin, epithelial membrane antigen, human milk fat globule, Leu-M1, TAG-72 (identified by monoclonal antibody B72.3), beta 1 pregnancy-specific glycoprotein (SP1), human placental lactogen, secretory component (SC), CA19-9, and S-100 protein were used. Twenty-one adenocarcinomas (91.3%) reacted for CEA, 14 (60.9%) for Leu-M1, 14 (60.9%) for SC, nine (39.1%) for CA19-9, and eight (34.8%) for SP1; no mesotheliomas stained for any of these markers. Nineteen adenocarcinomas (82.6%) and one mesothelioma (5.3%) reacted with B72.3. Adenocarcinomas and mesotheliomas did not significantly vary in reaction to the remaining antibodies. None of the antibodies used was specific for mesothelioma, but CEA was the single most useful marker. One of the two adenocarcinomas negative for CEA was positive for TAG-72, Leu-M1, and SC, and the only B72.3-positive mesothelioma was negative for CEA, Leu-M1, SC, CA19-9, and SP1. These findings indicate that greater sensitivity in differentiating mesothelioma and adenocarcinoma can be achieved by immunostaining for both CEA and one or more of the markers TAG-72 (B72.3), Leu-M1, SC (these three have the highest sensitivity and specificity after CEA), CA19-9, and SP1.
Similar articles
-
[Malignant mesothelioma of the pleura. Analysis of its immunohistochemical aspects].Ann Pathol. 1990;10(1):20-7. Ann Pathol. 1990. PMID: 2328062 French.
-
Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.Hum Pathol. 2001 May;32(5):529-36. doi: 10.1053/hupa.2001.24329. Hum Pathol. 2001. PMID: 11381372
-
Malignant mesothelioma: immunohistochemistry and DNA ploidy analysis as methods to differentiate mesothelioma from benign reactive mesothelial cell proliferation and adenocarcinoma in pleural and peritoneal effusions.Arch Pathol Lab Med. 1996 Oct;120(10):959-66. Arch Pathol Lab Med. 1996. PMID: 12046609
-
[Immunohistochemistry of mesotheliomas. Technique and current diagnostic contribution of immunohistochemical markers. General review].Arch Anat Cytol Pathol. 1993;41(5-6):212-22. Arch Anat Cytol Pathol. 1993. PMID: 8135582 Review. French.
-
[Comparative study of the expression of CEA and a myelomonocytic antigen (CD15) in serous effusions using two monoclonal antibodies NEO 723 and Leu M1].Arch Anat Cytol Pathol. 1992;40(4):183-9. Arch Anat Cytol Pathol. 1992. PMID: 1294046 Review. French.
Cited by
-
Performance enhancement of classifiers through Bio inspired feature selection methods for early detection of lung cancer from microarray genes.Heliyon. 2024 Aug 17;10(16):e36419. doi: 10.1016/j.heliyon.2024.e36419. eCollection 2024 Aug 30. Heliyon. 2024. PMID: 39262982 Free PMC article.
-
Immunocytochemistry of effusion fluids: Introduction to SCIP approach.Cytojournal. 2022 Jan 31;19:3. doi: 10.25259/CMAS_02_05_2021. eCollection 2022. Cytojournal. 2022. PMID: 35541032 Free PMC article. Review.
-
Guidelines for the diagnosis and treatment of malignant pleural mesothelioma.J Thorac Dis. 2013 Dec;5(6):E254-307. doi: 10.3978/j.issn.2072-1439.2013.11.28. J Thorac Dis. 2013. PMID: 24416529 Free PMC article. Review. No abstract available.
-
Immunocytochemical characterization of malignant mesothelioma and carcinoma metastatic to the pleura: IOB3--a new tumor marker.Lung. 1995;173(2):79-87. doi: 10.1007/BF02981468. Lung. 1995. PMID: 7536281
-
Pleural mesothelioma in a nine-month-old dog.Ir Vet J. 2007 Jan 1;60(1):30-3. doi: 10.1186/2046-0481-60-1-30. Ir Vet J. 2007. PMID: 21851687 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Medical